Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.
